(Hypertension. 1999;33:335-339.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
Angiotensin II Type 1 Receptor–Mediated Peroxide Production in Human Macrophages
From the Department of Geriatric Medicine (Y.Y., H.R., A.O., K.M., S.T., M.O., J.H., T.O.) and the Department of Biochemistry (K.S.), Osaka (Japan) University Medical School.
Correspondence to Jitsuo Higaki, MD, Department of Geriatric Medicine, Osaka University Medical School, 2-2 Yamadaoka, Suita 565-0871, Japan. E-mail higaki{at}geriat.med.osaka-u.ac.jp
Abstract—Our previous experiments demonstrated upregulation of the renin-angiotensin system in macrophages, including angiotensin II type 1 (AT1) and type 2 (AT2) receptors, during transformation from monocytes. We investigated the role of angiotensin II in oxidative stress of monocytes/macrophages, which plays a role in the advance of atherosclerosis. THP1, a human monocytic leukemia cell line, was differentiated to macrophages by adding of phorbol 12-myristate 13-acetate for 24 hours. The intracellular production of peroxide was measured by a cytofluorometric assay with 2',7'-dichlorofluorescein-diacetate with a flow cytometer scan. Peroxide was detected in monocytes and upregulated during the transformation to macrophages by 3.18±0.52 times in relative fluorescein of peak value (P<0.01). Angiotensin II (1 µmol/L) induced oxidative stress in macrophages, with the peak at 15 minutes by 451±223%, and returned to the control level within 1 hour. EC50 was 5.4x10-9 mol/L. AT1 antagonist (CV11974, 1 µmol/L) significantly decreased angiotensin II–induced oxidative stress in macrophages, but AT2 antagonist (PD123319, 1 µmol/L) did not. Of interest, AT1 antagonist also decreased basal levels of peroxide production in macrophages in a dose-dependent manner. These results suggest that upregulation of the expression of AT1 receptor in macrophages contributes in part to upregulation of peroxide production. AT1 receptor antagonists may be useful to suppress oxidative stress of macrophages in atherosclerotic lesions.
Key Words: angiotensin II • receptor antagonists • peroxide • atherosclerosis • macrophages
This article has been cited by other articles:
 |
|
 |
|
  Y. Nuki, T.-L. Tsou, C. Kurihara, M. Kanematsu, Y. Kanematsu, and T. Hashimoto Elastase-Induced Intracranial Aneurysms in Hypertensive Mice Hypertension, December 1, 2009; 54(6): 1337 - 1344. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. GLUBA, M. BANACH, D. P. MIKHAILIDIS, and J. RYSZ Genetic Determinants of Cardiovascular Disease: The Renin-Angiotensin-Aldosterone System, Paraoxonases, Endothelin-1, Nitric Oxide Synthase and Adrenergic Receptors In Vivo, September 1, 2009; 23(5): 797 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Foster, S. R. Lea, P. M. Preshaw, and J. J. Taylor Pivotal Advance: Vasoactive intestinal peptide inhibits up-regulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages J. Leukoc. Biol., April 1, 2007; 81(4): 893 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tone, K. Shikata, D. Ogawa, S. Sasaki, R. Nagase, M. Sasaki, K. Yozai, H. Kataoka Usui, S. Okada, J. Wada, et al. Changes of gene expression profiles in macrophages stimulated by angiotensin II -- Angiotensin II induces MCP-2 through AT1-receptor Journal of Renin-Angiotensin-Aldosterone System, March 1, 2007; 8(1): 45 - 50. [Abstract] [PDF]
|
|
|
|
 |
|
 L. A. Cassis, D. L. Rateri, H. Lu, and A. Daugherty Bone Marrow Transplantation Reveals That Recipient AT1a Receptors Are Required to Initiate Angiotensin II-Induced Atherosclerosis and Aneurysms Arterioscler Thromb Vasc Biol, February 1, 2007; 27(2): 380 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Teissier, A. Nohara, G. Chinetti, R. Paumelle, B. Cariou, J.-C. Fruchart, R. P. Brandes, A. Shah, and B. Staels Peroxisome Proliferator-Activated Receptor {alpha} Induces NADPH Oxidase Activity in Macrophages, Leading to the Generation of LDL with PPAR-{alpha} Activation Properties Circ. Res., December 10, 2004; 95(12): 1174 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yasunari, K. Maeda, T. Watanabe, M. Nakamura, J. Yoshikawa, and A. Asada Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy J. Am. Coll. Cardiol., June 2, 2004; 43(11): 2116 - 2123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Keidar, M. Kaplan, E. Pavlotzky, R. Coleman, T. Hayek, S. Hamoud, and M. Aviram Aldosterone Administration to Mice Stimulates Macrophage NADPH Oxidase and Increases Atherosclerosis Development: A Possible Role for Angiotensin-Converting Enzyme and the Receptors for Angiotensin II and Aldosterone Circulation, May 11, 2004; 109(18): 2213 - 2220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Otsuka, H Takahashi, M Shiratori, H Chiba, and S Abe Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist Thorax, January 1, 2004; 59(1): 31 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hayek, E. Pavlotzky, S. Hamoud, R. Coleman, S. Keidar, M. Aviram, and M. Kaplan Tissue Angiotensin-Converting-Enzyme (ACE) Deficiency Leads to a Reduction in Oxidative Stress and in Atherosclerosis: Studies in ACE-Knockout Mice Type 2 Arterioscler Thromb Vasc Biol, November 1, 2003; 23(11): 2090 - 2096. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Hayashi, K Sohmiya, A Ukimura, S Endoh, T Mori, H Shimomura, M Okabe, F Terasaki, and Y Kitaura Angiotensin II receptor blockade prevents microangiopathy and preserves diastolic function in the diabetic rat heart Heart, October 1, 2003; 89(10): 1236 - 1242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Proudfoot, K. D. Croft, I. B. Puddey, and L. J. Beilin Angiotensin II Type 1 Receptor Antagonists Inhibit Basal As Well As Low-Density Lipoprotein and Platelet-Activating Factor-Stimulated Human Monocyte Chemoattractant Protein-1 J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 846 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Suzuki, H. Nishimatsu, H. Satonaka, K. Walsh, A. Goto, M. Omata, T. Fujita, R. Nagai, and Y. Hirata Angiotensin II Induces Myocyte Enhancer Factor 2- and Calcineurin/Nuclear Factor of Activated T Cell-Dependent Transcriptional Activation in Vascular Myocytes Circ. Res., May 17, 2002; 90(9): 1004 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Papademetriou Selection of Antihypertensive Therapy for Patients With Hypertensive Renal Disease JAMA, June 6, 2001; 285(21): 2774 - 2776. [Full Text] [PDF]
|
|
|
|
|
|
M.-S. Zhou, A. Adam, and L. Raij Review: Interaction among angiotensin II, nitric oxide and oxidative stress Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S59 - S63. [PDF]
|
|
|
|
|
|
D. Casellas, A. Herizi, A. Artuso, A. Mimran, and B. Jover Candesartan prevents L-NAME-induced cardio-renal injury in spontaneously hypertensive rats beyond hypotensive effects Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S84 - S90. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Fischer, A. A. MacLean, M. Liu, B. Kalirai, and S. Keshavjee Inhibition of angiotensin-converting enzyme by captopril: A novel approach to reduce ischemia-reperfusion injury after lung transplantation J. Thorac. Cardiovasc. Surg., September 1, 2000; 120(3): 573 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Galle and K. Heermeier Angiotensin II and oxidized LDL: an unholy alliance creating oxidative stress Nephrol. Dial. Transplant., November 1, 1999; 14(11): 2585 - 2589. [Full Text] [PDF]
|
|
|
|
|
|
A. Faggiotto and R. Paoletti Statins and Blockers of the Renin-Angiotensin System : Vascular Protection Beyond Their Primary Mode of Action Hypertension, October 1, 1999; 34(4): 987 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Rodriguez-Iturbe, Y. Quiroz, M. Nava, L. Bonet, M. Chavez, J. Herrera-Acosta, R. J. Johnson, and H. A. Pons Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats Am J Physiol Renal Physiol, February 1, 2002; 282(2): F191 - F201. [Abstract] [Full Text] [PDF]
|
|